Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Prenetics Global Limited
Prenetics Global Limited News
Sep 12, 2025 - globenewswire.com
Prenetics Announces Second Quarter 2025 Financial Results with IM8 on Track to Achieve $100M Annual Recurring Revenue by Year's End
Sep 4, 2025 - prnewswire.com
HONEYWELL ANNOUNCES $600 MILLION CAPITAL RAISE FOR QUANTINUUM AT $10B PRE-MONEY EQUITY VALUATION TO ADVANCE QUANTUM COMPUTING AT SCALE
Prenetics Global Limited Quantitative Score
About Prenetics Global Limited
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Prenetics Global Limited Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Prenetics Global Limited Financials
Table Compare
Compare PRE metrics with: | |||
|---|---|---|---|
Earnings & Growth | PRE | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | PRE | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | PRE | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | PRE | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Prenetics Global Limited Income
Prenetics Global Limited Balance Sheet
Prenetics Global Limited Cash Flow
Prenetics Global Limited Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Prenetics Global Limited Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 0.2408 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2016-03-01 | 0.0602 | Quarterly |
| 2015-12-01 | 0.0602 | Quarterly |
| 2015-09-01 | 0.0602 | Quarterly |
| 2015-06-01 | 0.0602 | Quarterly |
| 2015-02-27 | 0.0602 | Quarterly |
Historical Market Cap
Shares Outstanding
Prenetics Global Limited Executives
| Name | Role |
|---|---|
| Mr. Hoi Chun Lo | Chief Financial Officer |
| Dr. Senthil Kumar Sundaram M.D. | Chief Clinical Officer |
| Ms. Samantha Kwok | Chief of Staff to Group Chief Executive Officer & Vice President of People & Operations |
| Mr. David Eric Vanderveen | Director & President of Americas |
| Mr. Sheng Wu Yeung | Co-Founder, Chairperson & Chief Executive Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Hoi Chun Lo | Chief Financial Officer | Male | 1986 | -- |
| Dr. Senthil Kumar Sundaram M.D. | Chief Clinical Officer | 1974 | -- | |
| Ms. Samantha Kwok | Chief of Staff to Group Chief Executive Officer & Vice President of People & Operations | Female | -- | |
| Mr. David Eric Vanderveen | Director & President of Americas | Male | 1969 | -- |
| Mr. Sheng Wu Yeung | Co-Founder, Chairperson & Chief Executive Officer | Male | 1979 | -- |
Prenetics Global Limited Insider Trades
| Date | 18 Mar |
| Name | MONTUPET JEAN PAUL L |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 18434 |
| Date | 18 Mar |
| Name | MONTUPET JEAN PAUL L |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 1750 |
| Date | 18 Mar |
| Name | MONTUPET JEAN PAUL L |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 12659 |
| Date | 18 Mar |
| Name | MONTUPET JEAN PAUL L |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 4459 |
| Date | 18 Mar |
| Name | MONTUPET JEAN PAUL L |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 9804 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 18 Mar | MONTUPET JEAN PAUL L | Director | Disposed | D-Return | 18434 |
| 18 Mar | MONTUPET JEAN PAUL L | Director | Disposed | D-Return | 1750 |
| 18 Mar | MONTUPET JEAN PAUL L | Director | Disposed | D-Return | 12659 |
| 18 Mar | MONTUPET JEAN PAUL L | Director | Disposed | D-Return | 4459 |
| 18 Mar | MONTUPET JEAN PAUL L | Director | Disposed | D-Return | 9804 |